NCT07762638AvailableNot Applicable
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Available
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Study Overview
Brief Summary
This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 3
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry diseaseFabry disease2024-513884-20-00Idorsia Pharmaceuticals Ltd.45
Recruiting
Phase 2
Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene TherapyFabry Disease (X-linked lysosomal storage disease).2024-512700-18-00Sangamo Therapeutics Inc.1
Enrolling By Invitation
Not Applicable
Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF)Fabry DiseaseNCT07560956Vastra Gotaland Region35
Not yet recruiting
Phase 2
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)NCT07353437Fudan University334
Not yet recruiting
Not Applicable
Care Pathway for Patients With Fabry's Disease (Fabry-PATH)Fabry DiseaseNCT07485660University Hospital, Toulouse200